(NVLS) - Earnings & Price History

NVLS: - 2.4, $0.00M, 0.05 (2.13%)

Sector: Healthcare - Industry: Biotechnology

Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product candidate is N91115, a small molecule that is in Phase II clinical trial, which addresses a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.Key Statistics

Past NVLS reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2016-11-03-0.595.225.195.155.155.3-0.77%▲1.36%0.58%21.31K
2016-11-02-0.595.195.61995.3855.15.55-4.18%▲-3.62%-7.65%70.08K
2016-11-01-0.595.61995.885.95.516.0180.34%▲-4.75%-4.42%25.39K
2016-10-31-0.595.885.935.95.86.07-0.51%-0.34%-0.84%17.31K
2016-08-01-0.524.814.764.714.714.86-1.05%2.12%1.05%13.52K

Login | Register
Monday Dec 10, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades